Alterations in Glutathione Levels and Apoptotic Regulators Are Associated with Acquisition of Arsenic Trioxide Resistance in Multiple Myeloma

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Matulis, Shannon M ^a   Morales, Alejo A ^b   Yehiayan, Lucy ^c   Lee, Kelvin P ^d   Cai, Yong ^c   Boise, Lawrence H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ARSENIC TRIOXIDE; BCL2 RELATED PROTEIN A1; BORTEZOMIB; DARINAPARSIN; DOXORUBICIN; GLUTATHIONE; MELPHALAN; PROTEIN NOXA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFECT; GENETIC ASSOCIATION; IC 50; MULTIPLE MYELOMA; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; MELPHALAN; MULTIPLE MYELOMA; OXIDES; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84871376638     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052662     Document Type: Article

References (42)

1. Chen SJ, Zhou GB, Zhang XW, Mao JH, de The H, et al. (2011) From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 117: 6425-6437.
2. Waxman S, Anderson KC, (2001) History of the development of arsenic derivatives in cancer therapy. The oncologist 6Suppl 2: 3-10.
3. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, et al. (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328: 240-243.
4. Lallemand-Breitenbach V, Zhu J, Chen Z, de The H, (2012) Curing APL through PML/RARA degradation by As2O3. Trends in molecular medicine 18: 36-42.
5. Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, et al. (2002) Expanding the use of arsenic trioxide: leukemias and beyond. Seminars in hematology 39: 22-26.
6. Anderson KC, Boise LH, Louie R, Waxman S, (2002) Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer journal 8: 12-25.
7. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, et al. (1999) Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer research 59: 1041-1048.
8. Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, et al. (2000) Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer research 60: 3065-3071.
9. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, et al. (2001) Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98: 805-813.
10. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI, (2002) Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clinical cancer research: an official journal of the American Association for Cancer Research 8: 566-572.
11. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, et al. (2002) Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clinical cancer research: an official journal of the American Association for Cancer Research 8: 3658-3668.
12. Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, et al. (2002) Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 16: 1835-1837.
13. Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, et al. (2004) A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 18: 1518-1521.
14. Abou-Jawde RM, Reed J, Kelly M, Walker E, Andresen S, et al. (2006) Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Medical oncology 23: 263-272.
15. Berenson JR, Boccia R, Siegel D, Bozdech M, Bessudo A, et al. (2006) Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. British journal of haematology 135: 174-183.
16. Miller WH Jr, (2002) Molecular targets of arsenic trioxide in malignant cells. The oncologist 7Suppl 1: 14-19.
17. Akay C, Gazitt Y, (2003) Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell cycle 2: 358-368.
18. Liu Q, Hilsenbeck S, Gazitt Y, (2003) Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101: 4078-4087.
19. McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, et al. (2003) Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Molecular cancer therapeutics 2: 1155-1164.
20. Kircelli F, Akay C, Gazitt Y, (2007) Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53. International journal of oncology 30: 993-1001.
21. Morales AA, Gutman D, Lee KP, Boise LH, (2008) BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 111: 5152-5162.
22. Ge F, Lu XP, Zeng HL, He QY, Xiong S, et al. (2009) Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. Journal of proteome research 8: 3006-3019.
23. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, et al. (1995) CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3: 87-98.
24. Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, et al. (2009) Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Molecular cancer therapeutics 8: 1197-1206.
25. Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH, (2009) Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. The Journal of biological chemistry 284: 12886-12895.
26. Nguyen T, Nioi P, Pickett CB, (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. The Journal of biological chemistry 284: 13291-13295.
27. Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, et al. (2008) Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 112: 2450-2462.
28. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S, (2002) Mechanisms of action of arsenic trioxide. Cancer research 62: 3893-3903.
29. Davison K, Cote S, Mader S, Miller WH, (2003) Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 17: 931-940.
30. Uotila L, Koivusalo M, (1974) Formaldehyde dehydrogenase from human liver. Purification, properties, and evidence for the formation of glutathione thiol esters by the enzyme. The Journal of biological chemistry 249: 7653-7663.
31. Lu SC, (2009) Regulation of glutathione synthesis. Molecular aspects of medicine 30: 42-59.
32. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR, (2010) The BCL-2 family reunion. Molecular cell 37: 299-310.
33. Adams JM, Cory S, (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337.
34. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, et al. (2005) High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. International journal of cancer Journal international du cancer 113: 730-737.
35. Yecies D, Carlson NE, Deng J, Letai A, (2010) Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115: 3304-3313.
36. Chonghaile TN, Letai A, (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene 27Suppl 1: S149-157.
37. Vogler M, (2012) BCL2A1: the underdog in the BCL2 family. Cell death and differentiation 19: 67-74.
38. Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, et al. (1992) Mutations of the p53 gene in human myeloma cell lines. Oncogene 7: 1015-1018.
39. Mulcahy RT, Bailey HH, Gipp JJ, (1994) Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer chemotherapy and pharmacology 34: 67-71.
40. Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, et al. (2003) Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer research 63: 7900-7906.
41. Bellamy WT, Dorr RT, Dalton WS, Alberts DS, (1988) Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. Cancer research 48: 6360-6364.
42. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, et al. (2001) cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. The Journal of pharmacology and experimental therapeutics 299: 434-441.